Advaxis, Inc. (ADXS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ken Berlin
Employees:
10
9 DEER PARK DRIVE, SUITE K-1, MONMOUTH JUNCTION, NJ, 08852
732 545 1590

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Advaxis, Inc. focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer.

Data derived from most recent annual or quarterly report
Market Cap 435.828 Thousand Shares Outstanding1.816 Million Avg 30-day Volume 3.666 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-8.46
Price to Revenue672.3474 Debt to Equity0.0 EBITDA-16.827 Million
Price to Book Value56.0174 Operating Margin-579.8148 Enterprise Value2.137 Billion
Current Ratio5.49 EPS Growth0 Quick Ratio5.281
1 Yr BETA 1.1993 52-week High/Low 1.57 / 0.24 Profit Margin-551.2963
Operating Cash Flow Growth29.6308 Altman Z-Score152.5093 Free Cash Flow to Firm -5.422 Million
View SEC Filings from ADXS instead.

View recent insider trading info

Advaxis, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADXS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADXS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-01-30 by AMOON 2 FUND LIMITED PARTNERSHIP
  • 4: filed on 2023-01-23 by SIDRANSKY DAVID
  • 4: filed on 2023-01-23 by GOLDBERG MURRAY A
  • 4: filed on 2023-01-23 by BISKER-LEIB VERED
  • 4: filed on 2023-01-23 by SPIEGEL ROBERT J.
  • 3: filed on 2023-01-23 by GOLDBERG MURRAY A
  • 3: filed on 2023-01-23 by BISKER-LEIB VERED
  • 3: filed on 2023-01-23 by SPIEGEL ROBERT J.
  • 3: filed on 2021-02-16 by GITELMAN IGOR
  • 4: filed on 2020-05-05 by HENDERSON MOLLY

    • Events (8k)

  • 8-K: filed on 2023-01-30:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
  • 8-K: filed on 2023-01-25:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-01-12:
    Item 8.01: Other Events
  • 8-K: filed on 2022-12-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-24:
    Item 8.01: Other Events
  • 8-K: filed on 2022-06-06:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GOLDBERG MURRAY A

    • Director
    		 0 2023-01-19 2

    SIDRANSKY DAVID

    • Director
    		 139 2023-01-19 1

    SPIEGEL ROBERT J.

    • Director
    		 0 2023-01-19 2

    AMOON GROWTH FUND LIMITED PARTNERSHIP

    SCHINDEL YAIR CHAIM

    • 10% Owner
    		 560,602 2023-01-19 1

    BISKER-LEIB VERED

    • Director
    		 0 2023-01-19 2

    GITELMAN IGOR CHIEF ACCOUNTING OFFICER

    • Officer
    		 0 2021-02-11 0

    BERMAN RICHARD J

    • Director
    		 0 2020-05-04 0

    APPEL RONI

    • Director
    		 0 2020-05-04 0

    PATTON JAMES P

    • Director
    		 0 2020-05-04 0

    HENDERSON MOLLY EXECUTIVE VICE PRESIDENT & CFO

    • Officer
    		 0 2020-05-04 0

    KHLEIF SAMIR N

    • Director
    		 0 2020-05-04 0

    BERLIN KENNETH A PRESIDENT AND CEO

    • Officer
    		 0 2020-05-04 0

    GUTIERREZ ANDRES EXECUTIVE VICE PRESIDENT & CMO

    • Officer
    		 0 2020-05-04 0

    PETIT ROBERT CHIEF SCIENTIFIC OFFICER

    • Officer
    		 231,206 2018-11-05 0

    LOMBARDO ANTHONY A INTERIM CEO

    • Officer
    		 81,852 2018-04-17 0

    BONSTEIN SARA CHIEF FINANCIAL OFFICER

    • Officer
    		 226,670 2018-03-29 0

    MCKEARN THOMAS J

    • Director
    		 0 2017-11-02 0

    RIDGE THOMAS J

    • Director
    		 0 2017-11-02 0

    ADAGE CAPITAL PARTNERS GP, L.L.C.

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    		 No longer subject to file 2017-10-11 0

    O'CONNOR DANIEL CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 618,352 2017-06-30 0

    MAYES, GREGORY T.

    • Director
    		 103,841 2016-12-30 0

    MAURO DAVID J CHIEF MEDICAL OFFICER

    • Officer
    		 166,271 2015-12-31 0

    FRENCH CHRISTY LEE VP-REGULATORY, MEDICAL AFFAIRS

    • Officer
    		 71,938 2014-12-31 0

    MOORE THOMAS A

    • FORMER DIRECTOR
    		 176,462 2014-07-17 0

    ROSENBLUM MARK J CHIEF FINANCIAL OFFICER

    • Officer
    		 113,774 2014-01-31 0

    ROTHMAN JOHN F EXEC VP OF SCIENCE AND OPS

    • Officer
    		 0 2011-11-08 0

    COBB FREDRICK D VICE PRESIDENT FINANCE

    • Officer
    		 0 2009-07-21 0

    WADE MARTIN R III

    • Director
    		 0 2006-03-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADVAXIS INC ADXSD 2022-07-05 22:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 21:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 21:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 20:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 20:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 19:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 19:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 18:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 18:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 17:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 17:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 16:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 16:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 15:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 15:15:04 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 14:45:04 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 14:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 13:45:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 13:15:03 UTC -0.9008 2.4708 40000
    ADVAXIS INC ADXSD 2022-07-05 12:45:03 UTC -0.9008 2.4708 40000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments